Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II first-in-human study of INV-6452 in HR-positive/HER2-negative advanced breast cancer and advanced solid tumors
CTR20251225Phase 2Active
- Sponsor
- Guangdong Institute of Innovative Drug Translational Medicine
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of INV-6452 in breast cancer, Nonhematologic neoplasms, sponsored by Guangdong Institute of Innovative Drug Translational Medicine. Started Jul 2025; status: active.
02
Drugs
INV-6452
03
Conditions
breast cancerNonhematologic neoplasms
Beyond the preview
Go deeper on CTR20251225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251225.